论文部分内容阅读
目的：评价小剂量重组组织型纤溶酶原激活物（ｒｔＰＡ）静脉溶栓治疗国人急性心肌梗死（ＡＭＩ）的疗效及安全性。方法：６６例ＡＭＩ患者随机分为ｒｔＰＡ组３１例及尿激酶（ＵＫ）组３５例，分别应用ｒｔＰＡ及ＵＫ治疗。结果：心肌梗死相关血管再通率ｒｔＰＡ组８０．６％与ＵＫ组４８．６％比较，Ｐ＜０．０５；４周住院病死率ｒｔＰＡ组０与ＵＫ组８．６％比较，Ｐ＜０．０５；而２组间出血发生率无差异。结论：小剂量ｒｔＰＡ治疗ＡＭＩ血管再通率高，出血并发症少，可降低ＡＭＩ早期病死率，是一种安全有效的溶栓剂
PURPOSE: To evaluate the efficacy and safety of intravenous thrombolytic therapy of low dose recombinant tissue plasminogen activator (rtPA) in patients with acute myocardial infarction (AMI) in China. Methods: Sixty-six patients with AMI were randomly divided into rtPA group (n = 31) and urokinase group (urokinase group). 35 patients were treated with rtPA and UK respectively. Results: Compared with 48.6% in UK group, 80.6% in rtPA group was significantly lower than that in UK group (P <0.05); 4-week in-hospital mortality rate in rtPA group was significantly higher than that in UK group (8.6%, P <0 .05; there was no difference in the incidence of bleeding between the two groups. CONCLUSION: A small dose of rtPA is a safe and effective thrombolytic agent for the treatment of AMI with high recanalization rate and less bleeding complications, which can reduce the early mortality of AMI